Using existing drugs in a new way to treat high-risk acute lymphoblastic leukaemia
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.
Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.
Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.